{"protocolSection":{"identificationModule":{"nctId":"NCT05001347","orgStudyIdInfo":{"id":"TJ004309STM103"},"organization":{"fullName":"I-Mab Biopharma US Limited","class":"INDUSTRY"},"briefTitle":"A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors","officialTitle":"A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-11-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-02-08","type":"ACTUAL"},"completionDateStruct":{"date":"2023-02-08","type":"ACTUAL"},"studyFirstSubmitDate":"2021-07-12","studyFirstSubmitQcDate":"2021-08-04","studyFirstPostDateStruct":{"date":"2021-08-11","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-09-18","resultsFirstSubmitQcDate":"2025-11-21","resultsFirstPostDateStruct":{"date":"2025-12-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2025-11-21","lastUpdatePostDateStruct":{"date":"2025-12-16","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"I-Mab Biopharma US Limited","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.","detailedDescription":"This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors. This clinical study includes two cohorts: Cohort 1 will include Immuno-Oncology (IO) treatment naïve ovarian cancer (OC) patients who have progressed on or after platinum therapy; and Cohort 2 will include patients with head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), gastrointestinal cancer (GC), triple negative breast cancer (TNBC), or ovarian carcinoma (OC) with PD-L1 expression ≥ 1%. Additional cohorts for selected tumor types might be added later."},"conditionsModule":{"conditions":["Ovarian Cancer","Head and Neck Cancer","Non Small Cell Lung Cancer","Gastrointestinal Cancer","Triple Negative Breast Cancer","Ovarian Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":25,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"TJ004309 and Atezolizumab","type":"EXPERIMENTAL","description":"TJ004309 20 mg/kg Q3W in combination with atezolizumab 1200 mg Q3W","interventionNames":["Drug: TJ004309"]}],"interventions":[{"type":"DRUG","name":"TJ004309","description":"Antibody to CD73","armGroupLabels":["TJ004309 and Atezolizumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker Enriched Cohort of Subjects With Selected Tumor Types","description":"Anti-tumor activity of the combination of TJ004309 and atezolizumab was measured by objective response rate (ORR) based on RECIST 1.1","timeFrame":"Up to 66 weeks"}],"secondaryOutcomes":[{"measure":"o Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker Enriched Cohort of Subjects With Selected Tumor Types","description":"Anti-tumor activity of the combination of TJ004309 and atezolizumab was measured by objective response rate (ORR) based on iRECIST.","timeFrame":"Up to 66 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cohort 1: Patients with histologically confirmed epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer subjects with any high-grade serous component, progressed on or after platinum-containing therapy and not eligible for further platinum containing treatment (platinum-resistant, platinum-refractory disease defined by progression of disease on a platinum-containing regimen or recurrence of disease within 180 days of receiving the last dose of platinum-based treatment).\n* Cohort 2: Patients with selected tumor types that have relapsed or progressed after 2 lines of therapy or who are ineligible for other standard of care (SOC) therapies:\n\n  1. Histologically or cytologically confirmed metastatic NSCLC\n  2. Histologically or cytologically confirmed recurrent or metastatic HNSCC (oral cavity, oropharynx, hypopharynx, or larynx)\n  3. Histologically or cytologically confirmed metastatic or non-resectable advanced metastatic gastric or gastroesophageal adenocarcinoma\n  4. Histologically or cytologically confirmed unresectable, locally advanced or metastatic TNBC (confirmed HER2-negative, estrogen receptor-negative and progesterone receptor-negative)\n  5. Histologically confirmed ovarian cancer of all high-grade epithelial types who are IO treatment naïve and have progressed after 3 months on or after platinum-containing therapy\n  6. PD-L1 expression Tumor Proportion Score (TPS) ≥ 1% for NSCLC and Combined Proportion Score (CPS) ≥ 1% for all other tumor types\n  7. A 28-day washout period after the completion of programmed death-1 (PD-1)/PD-L1 therapy\n  8. Patients should have no more than 5 prior lines of therapies\n* Cohort 2 - (Optional for the ovarian cohort) Pre-treatment fresh tumor biopsies and paired treatment fresh tumor biopsies will be collected from at least 5 patients. Biopsy must be excisional, incisional, or core.\n\nExclusion Criteria:\n\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\], OX 40 \\[Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4)\\], CD137 \\[tumor necrosis factor receptor superfamily member 9 (TNFRSF9)\\]) (only applies to ovarian cancer patients in Cohorts 1 and 2)\n* Disease progression within 3 months of starting anti-PD-1 and anti-PD-L1 inhibitors\n* Known active or chronic Hepatitis B or Hepatitis C, other hepatitides (non-alcohol steatohepatitis, alcohol or drug-related, autoimmune) serology at screening or cirrhosis\n* Active autoimmune disease requiring systemic treatment within the past 12 months\n* Active interstitial lung disease (ILD) or pneumonitis or a history of ILD\n* Brain involvement with cancer, spinal cord compression, carcinomatous meningitis, or new evidence of brain or leptomeningeal disease; unless the lesion(s) have been radiated or resected, are considered fully treated and inactive, are asymptomatic, and no steroids have been administered for CNS disease over the 7 days prior to study treatment\n* Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment\n* Known human immunodeficiency virus (HIV) unless CD4+ T cell count \\> 350 cells/μL with an undetectable viral load","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Arizona Oncology Associates","city":"Tucson","state":"Arizona","zip":"85711","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Innovative Clinical Research Institute","city":"Whittier","state":"California","zip":"90603","country":"United States","geoPoint":{"lat":33.97918,"lon":-118.03284}},{"facility":"Medical Oncology Hematology Consultants, PA","city":"Newark","state":"Delaware","zip":"19713","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Illinois Cancer Specialists","city":"Arlington Heights","state":"Illinois","zip":"60005","country":"United States","geoPoint":{"lat":42.08836,"lon":-87.98063}},{"facility":"Women's Cancer Care","city":"Covington","state":"Louisiana","zip":"70433","country":"United States","geoPoint":{"lat":30.47549,"lon":-90.10042}},{"facility":"Maryland Oncology Hematology","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Laura and Isaac Perlmutter Cancer Center at NYU Langone","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke Cancer Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Tri County Hematology and Oncology Associates","city":"Massillon","state":"Ohio","zip":"44646","country":"United States","geoPoint":{"lat":40.79672,"lon":-81.52151}},{"facility":"Texas Oncology - Arlington North","city":"Arlington","state":"Texas","zip":"76012","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"Texas Oncology - Austin Central","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Texas Oncology - Forth Worth Cancer Center","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Texas Oncology - The Woodlands, Gynecologic Oncology","city":"The Woodlands","state":"Texas","zip":"77380","country":"United States","geoPoint":{"lat":30.15799,"lon":-95.48938}},{"facility":"Virginia Cancer Specialists","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Northwest Cancer Specialists","city":"Vancouver","state":"Washington","zip":"98684","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Cohort 1","description":"Platinum resistant or refractory IO naive ovarian carcinoma (OC)\n\nTJ004309 20mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W"},{"id":"FG001","title":"Cohort 2","description":"HNSCC, NSCLC, GC, TNBC, OC\n\nTJ004309 20 mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"6"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cohort 1","description":"Platinum resistant or refractory IO naive ovarian carcinoma (OC)\n\nTJ004309 20mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W"},{"id":"BG001","title":"Cohort 2","description":"HNSCC, NSCLC, GC, TNBC, OC\n\nTJ004309 20 mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"25"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"11"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.7","spread":"10.84"},{"groupId":"BG001","value":"60.0","spread":"11.35"},{"groupId":"BG002","value":"63.2","spread":"11.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"20"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"22"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"19"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Region of Enrollment","description":"United States","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"25"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"To Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker Enriched Cohort of Subjects With Selected Tumor Types","description":"Anti-tumor activity of the combination of TJ004309 and atezolizumab was measured by objective response rate (ORR) based on RECIST 1.1","populationDescription":"Efficacy evaluable analysis set was defined as all patients who received at least one dose of study drug and undergo at least one post-baseline tumor assessment. Patients who died before the first scheduled post-baseline tumor assessment were also included in the efficacy evaluable analysis set- only 23 of the 25 subjects were efficacy evaluable per this definition.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 66 weeks","groups":[{"id":"OG000","title":"Cohort 1","description":"Platinum resistant or refractory IO naive ovarian carcinoma (OC)\n\nTJ004309 20mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W"},{"id":"OG001","title":"Cohort 2","description":"HNSCC, NSCLC, GC, TNBC, OC\n\nTJ004309 20 mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"o Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker Enriched Cohort of Subjects With Selected Tumor Types","description":"Anti-tumor activity of the combination of TJ004309 and atezolizumab was measured by objective response rate (ORR) based on iRECIST.","populationDescription":"Overall number of participants is the number of subjects who had at least one response assessment (iRECIST) from N=6 out 15 in Cohort 1 and N=4 out of 8 in Cohort 2","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 66 weeks","groups":[{"id":"OG000","title":"Cohort 1","description":"Platinum resistant or refractory IO naive ovarian carcinoma (OC)\n\nTJ004309 20mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W"},{"id":"OG001","title":"Cohort 2","description":"HNSCC, NSCLC, GC, TNBC, OC\n\nTJ004309 20 mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"15 months","eventGroups":[{"id":"EG000","title":"Cohort 1","description":"Platinum resistant or refractory IO naive ovarian carcinoma (OC)\n\nTJ004309 20mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W","deathsNumAffected":4,"deathsNumAtRisk":17,"seriousNumAffected":7,"seriousNumAtRisk":17,"otherNumAffected":0,"otherNumAtRisk":17},{"id":"EG001","title":"Cohort 2","description":"HNSCC, NSCLC, GC, TNBC, OC\n\nTJ004309 20 mg/kg Q3W and atezolizumab 1200 mg/flat dose Q3W","deathsNumAffected":2,"deathsNumAtRisk":8,"seriousNumAffected":4,"seriousNumAtRisk":8,"otherNumAffected":0,"otherNumAtRisk":8}],"seriousEvents":[{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":17},{"groupId":"EG001","numAffected":2,"numAtRisk":8}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":8}]},{"term":"Infusion-related reaction","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":8}]},{"term":"Cardiac Failure congestive","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":8}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":8}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":8}]},{"term":"Biliary Obstruction","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":8}]},{"term":"Pneumonia","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":8}]},{"term":"Ureteric obstruction","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":8}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":8}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"VP of Clinical Development","organization":"I-Mab Biopharma","email":"us.info@imabbio.com","phone":"240-745-6330"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-09-30","uploadDate":"2025-05-30T09:08","filename":"Prot_000.pdf","size":1665579},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-11-22","uploadDate":"2025-05-30T09:14","filename":"SAP_001.pdf","size":1258870}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-10-07","type":"ESTIMATED"}}}},"conditionBrowseModule":{"meshes":[{"id":"D010051","term":"Ovarian Neoplasms"},{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D005770","term":"Gastrointestinal Neoplasms"},{"id":"D064726","term":"Triple Negative Breast Neoplasms"}],"ancestors":[{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D010049","term":"Ovarian Diseases"},{"id":"D000291","term":"Adnexal Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D005833","term":"Genital Neoplasms, Female"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006058","term":"Gonadal Disorders"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D001943","term":"Breast Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]}},"hasResults":true}